The last entry (and these have been in no particular order, by the way) is Allos Therapeutics (NASDAQ: ALTH). The pharmaceutical company is hard at work on technology that improves existing cancer medications. According to Hoovers Online, ALTH's current lead drug candidate -- PDX -- is in trials to combat T-cell lymphoma. Some of the firm's other proposed treatments work to fight solid tumors and lymphoma.
ALTH shares have zoomed higher since mid-September, benefiting from support at their short-term 10-day and 20-day moving averages. During Monday's market pullback, the stock managed a successful retest of its 10-day trendline. It's interesting to note as well that a test of the equity's 20-month moving average in the summer put the shares back in uptrending motion; ALTH has not closed below this trendline since November 2005.
One concern from a contrarian perspective is that covering analysts have already taken a shine to ALTH shares; all five of the brokerage firms following the stock have rated it a "buy" or better, leaving the equity vulnerable to downgrades. Additional broker coverage is also possible as well, however, and this could lift the profile of the outperforming but underappreciated shares.
10 stocks under $10: Bruker BioSciences (BRKR)
10 stocks under $10: TriQuint Semiconductor (TQNT)
10 stocks under $10: CBIZ Inc. (CBZ)
10 stocks under $10: Brigham Exploration (BEXP)
10 Stocks Under $10: Medical Staffing Network Holdings (MRN)
10 Stocks Under $10: Incyte (INCY)
10 Stocks Under $10: Art Technology Group (ARTG)
10 Stocks Under $10: Ampal-American Israel (AMPL)
10 Stocks Under $10: General Moly (GMO)
Beth Gaston Moon is an analyst at Schaeffer's Investment Research.